An observational study in Obesity; Drug, sponsored by University of Colorado, Denver. Not yet recruiting. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by University of Colorado, Denver · Observational
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Obesity by University of Colorado, Denver — 19 open to participants now, 32 under way, 2 of them phase 3. Obesity · University of Colorado, Denver.
Among the 105 studies in Obesity by University of Colorado, Denver, this one is the 17th largest by planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2025, is one of 17 observational ones, reaches primary completion later than 10 of the 31 other live ones, and was the 100th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →19 of the 105 studies in Obesity by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 25–45
University of Colorado, Denver · Sites in United States
Ages 18–65
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 12–24
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 25 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 4 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 61 across the 88 interventional studies, 54 across the 17 observational. Of the 68 that completed or were terminated, 27 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
11 of the studies in Obesity by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06116435University of Colorado, DenverA Pilot Factorial Trial of an Integrated Lifestyle Intervention | 2026-12 |
| NCT06856928University of Colorado, DenverImpact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites. | 2026-12 |
| NCT04791371University of Colorado, DenverRole of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes | 2027-01-15 |
| NCT07446595University of Colorado, DenverBfedBwell INSPIRE Pilot | 2027-03 |
| NCT05870982University of Colorado, DenverEarly vs. Late Time Restricted Eating vs. Daily Caloric Restriction | 2027-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 105 studies in Obesity by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.
Potential participants are residents of the Denver metropolitan area who have either:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the early group are individuals that have established agreements with their clinical providers to begin treatment with semaglutide or tirzepatide as part of their ongoing weight management strategy. These participants will complete a meal challenge before they start the medication and 6 weeks after starting medication.
Other: Meal Challenge
Participants in the late group are individuals that have lost \>12% of their body weight on either semaglutide or tirzepatide and are still taking the medication. These participants will complete a meal challenge before they discontinue medication and 3 weeks after discontinuing the medication.
Other: Meal Challenge
The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Participant Recruitment
Number of participants recruited for the study.
Time frame: 6-10 weeks
Meal test tolerability
Number or participants able to tolerate and complete the test meal.
Time frame: 6-10 weeks
Rate of protocol completion
Percentage of participants enrolled that complete the protocol
Time frame: 6-10 weeks
Change in peptide YY (pg/ml)
Time frame: 6-10 weeks
Change in Glucagon Like Peptide-1 (pg/mL)
Time frame: 6-10 weeks
Change in leptin (ng/mL)
Time frame: 6-10 weeks
Change in insulin (uIU/mL)
Time frame: 6-10 weeks
Change in Glucagon (pg/mL)
Time frame: 6-10 weeks
Glucose-Dependent Insulinotropic Peptide (pg/mL)
Time frame: 6-10 weeks
Change in Glucose (mg/dL)
Time frame: 6-10 weeks
Change in triglycerides (mg/dL)
Time frame: 6-10 weeks
Change in free fatty acids (uEq/L)
Time frame: 6-10 weeks
Change in Total Cholesterol (mg/dL)
Time frame: 6-10 weeks
Gastric emptying by acetaminophen
Peak acetaminophen concentration in blood
Time frame: 6-10 weeks
Eating Rate
Calories/minutes
Time frame: 6-10 weeks
Changes in subjective hunger by visual analog scale (VAS)
Line from 0: not hungry to 10: extremely hungry
Time frame: 6-10 weeks
Changes in subjective fullness by visual analog scale (VAS)
Line from 0: not full to 10: extremely full
Time frame: 6-10 weeks
Changes in perceived prospective food consumption by visual analog scale (VAS)
Line from 0: no desire to eat more to 10: I could eat a large amount.
Time frame: 6-10 weeks
Changes in subjective nausea by visual analog scale (VAS)
Line from 0: no nausea at all more to 10: worst nausea possible.
Time frame: 6-10 weeks
Disinhibition measured by TFEQ
Disinhibition
Time frame: 6-10 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Dec 2026, 21 months later.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 21 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →